Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

terminated267%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

NCT02738008
terminatedphase_2

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

NCT02604199
withdrawnphase_2

Study of ARC-520 in Patient With Chronic Hepatitis B Virus

NCT02349126

Clinical Trials (3)

Showing 3 of 3 trials
NCT02738008Phase 2

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

Terminated
NCT02604199Phase 2

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

Terminated
NCT02349126Phase 2

Study of ARC-520 in Patient With Chronic Hepatitis B Virus

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3